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Abstract: Giardia lamblia, a causative agent of persistent diarrhea in humans, domestic animals, and
cattle, is usually treated with nitro compounds. Consequently, enzymes involved in anaerobic nitro
reduction have been investigated in detail as potential targets. Their role within the normal metabolic
context is, however, not understood. Using 1H high-resolution magic angle spinning (HR-MAS)
NMR spectroscopy, we analyzed the metabolomes of G. lamblia trophozoites overexpressing three
nitroreductases (NR1–NR3) and thioredoxin reductase (TrxR), most likely a scavenger of reactive
oxygen species, as suggested by the results published in this study. We compared the patterns
to convenient controls and to the situation in the nitro drug resistant strain C4 where NR1 is
downregulated. We identified 27 metabolites in G. lamblia trophozoites. Excluding metabolites of high
variability among different wildtype populations, only trophozoites overexpressing NR1 presented a
distinct pattern of nine metabolites, in particular arginine catabolites, differing from the respective
controls. This pattern matched a differential pattern between wildtype and strain C4. This suggests
that NR1 interferes with arginine and thus energy metabolism. The exact metabolic function of NR1
(and the other nitroreductases) remains to be elucidated.
Keywords: amino acids; arginine; metabolism; giardia; HR-MAS; resistance
1. Introduction
Giardia lamblia is an anaerobic or microaerophilic unicellular diplomonad causing persistent
diarrhea in humans and various domestic animals. The life cycle comprises two stages, namely, the
pear-shaped, flagellated trophozoite proliferating in the upper part of the small intestine, and the
non-proliferative cyst representing the infectious stage of the parasite [1,2].
Analysis of the genome [3] has revealed prokaryote-like features such as short promoter sequences,
a nearly complete absence of introns, and high similarities of some key enzymes of energy and
intermediate metabolism, with prokaryotic enzymes most likely acquired by lateral transfer [4,5]. Thus,
it is not surprising that the metabolism of G. lamblia trophozoites has unusual features in comparison
to host cells. The anaerobic energy metabolism [6] is chemoheterotrophic yielding ethanol, acetic acid,
and alanine as fermentation end products. Moreover, arginine is used as the main energy supply via
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arginine deiminase (ADI), ornithine carbamoyl transferase, and carbamate kinase, as detailed in earlier
studies [7–9].
The treatment against giardiasis comprises nitro compounds such as metronidazole (MET), other
5-nitroimidazole compounds, or nitazoxanide (NTZ) [10,11]. Moreover, G. lamblia is susceptible to
a variety of antibiotics because of its prokaryote-like transcription and translation machineries, as
well as to albendazole [12]. According to a commonly accepted model, nitro compounds are activated
by reduction yielding toxic intermediates causing nitrosative stress [13,14]. Pyruvate ferredoxin
oxidoreductase (PFOR) is a main supplier of electrons [6,15]. This explains why knock-down of
this enzyme is correlated with increased resistance to MET [16]. Studies with resistant strains have
revealed, however, that resistance does not always correlate with reduced PFOR activity [17,18]. Other
enzymes potentially involved in the reduction of nitro drugs are the nitroreductases (NR)1 [19,20] and
NR2 [21,22]. Recently, a third homologue of NR1 and NR2 with weak nitroreductase activity, NR3,
has been described [23]. All three NRs have higher quinone reductase than nitroreductase activities
in vitro [22,23]. Overexpression of NR1 results in an increased susceptibility to nitro compounds
in Escherichia coli [19,22,23] and in G. lamblia [19,23], whereas overexpression of NR2 results in an
increased resistance in E. coli [21–23] in independent studies. Their function within the intermediary
metabolism under physiological conditions (i.e., in the absence of nitro drugs) is completely unknown.
Thioredoxin-reductase (TrxR) has nitroreductase activity in vitro [15]. Overexpression of the
wildtype allele in the G. lamblia strain WBC6 does not alter the susceptibility to NTZ and only slightly
alters the susceptibility to MET, and overexpression of a dominant negative mutant allele has no
effects on drug resistance [24]. In resistant strains of a different genetic background, however, TrxR is
overexpressed [25]. Specific functions are not known, to date.
In order to get an insight into potential functions of these enzymes, the first step would be to
compare metabolomic patterns of strains with altered expression levels of the respective genes. In a
previous study, we introduced high-resolution magic angle spinning (HR-MAS) NMR spectroscopy as
a suitable tool to study the metabolome of G. lamblia [26]. HR-MAS yields well-resolved liquid-like
1H-NMR spectra from semi-solid materials, reducing resonance line broadening effects caused by
dipolar interactions and magnetic susceptibility differences inherent to most semi-solid materials [27].
Therefore, HR-MAS NMR has become a very attractive tool in the analysis of small metabolites from
biological materials such as cells and tissue samples [28,29] or food samples [30–32]. Moreover, this
method has proven to be suitable for the determination of biomarkers for the metabolic response to
anticancer drugs [33–35].
Here, we present a metabolomic study using 1H HR-MAS NMR spectroscopy comparing transgenic
G. lamblia strains overexpressing genes encoding for thioredoxin reductase and nitroreductases.
Unfortunately, knock-down of the expression of the respective genes is not possible in our hands.
An exception is TrxR, where a dominant negative mutant allele exists, the gene product of which
forms an inactive complex with the wildtype TrxR. Another exception is the nitro drug resistant strain
G. lamblia C4 derived from the wildtype WBC6 [17], which has significantly reduced NR1 protein levels
when grown in the presence of NTZ [19,25].
In order to identify potential metabolomic patterns related to the overexpression of the respective
genes, we eliminated metabolites from the discussion that showed strong differences between
independent wildtype populations. Moreover, as we identified a distinct pattern in NR1 overexpressors
only, we tested the observed pattern by a comparison between the wildtype WBC6 and the derived
nitro drug-resistant strain C4. The strains used in this study are listed in Table 1.
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Table 1. List of the transgenic Giardia lamblia strains used in this study. All transgenes were fused to
the strong, constitutive arginine deiminase (ADI)-promotor. CDS, coding sequence; NR, nitroreductase;
TrxR, thioredoxin reductase; TrxR DN, dominant negative mutation of TrxR. Please note that we have
kept our original designations NR1, NR2, and NR3 to be in frame with our previous publications.
Strain Characteristics Accession References
WBC6 Wildtype strain (WT) No transgene
C4 Nitro drug-resistant strain derived from WT No transgene
GusA WT overexpressing E. coli glucuronidase A E. coli K-12 CDS 1785 074–1785 074
NR1 WT overexpressing G. lamblia Fd-NR2 (“NR1”)Higher susceptibility to nitro drugs in G. lamblia and E. coli Giardia DB 22677 [19,23]
NR2 WT overexpressing G. lamblia Fd-NR1 (“NR2”)Better resistance to nitro drugs in E. coli Giardia DB 6175 [21,23]
NR3 WT overexpressing G. lamblia NR family protein (“NR3”) Giardia DB 15307 [23]
TrxR WT overexpressing G. lamblia TrxR wildtype Giardia DB 9827 [24]
TrxR DN WT overexpressing G. lamblia TrxR-dominant negative alleleHigher susceptibility to oxygen Giardia DB 9827
[24]
This work
2. Results and Discussion
2.1. Relative Amounts of Identified Metabolites
Using 1H-HR-MAS NMR, we identified 27 metabolites in G. lamblia WBC6 trophozoites, as listed
in Table 2. The values of all individual integrals are available in the Supplementary Materials section
(Table S1). In order to discriminate “natural” metabolite differences between wildtype populations
from those related to transgenic modifications, we compared, in a first step, the metabolomes of two
completely independent populations of WBC6 wildtype trophozoites (Table 2).
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Table 2. Metabolites identified in G. lamblia WBC6 wildtype trophozoites (WT; two independent experiments), in trophozoites overexpressing thioredoxin reductase
(TrxR) or a dominant negative mutation of TrxR (TrxR DN) as a control, and in trophozoites overexpressing the nitroreductases NR1, NR2, NR3, or GusA as a control.
The values represent normalized integrated peak areas obtained by integration of 1H-NMR resonances. Values are given as mean values ± SD of arbitrary units for n
replicates as indicated. Metabolites with significant differences from the respective controls (i.e., TrxR DN for TrxR and GusA for the NRs) after Bonferroni correction
for multiple comparisons are printed in bold (ANOVA followed by t-tests; +, p < 0.05; ◦, p < 0.01; *, p < 0.001). TMA: trimethylamine.
Metabolite WT 1n = 10
WT 2
n = 4
TrxR
n = 10
TrxR_DN
n = 10
GusA
n = 6
NR1
n = 5
NR2
n = 6
NR3
n = 5
Carbohydrates and related
Acetate 0.77 ± 0.05 0.85 ± 0.03 0.57 ± 0.03 0.65 ± 0.04 * 0.65 ± 0.02 0.49 ± 0.02 * 0.58 ± 0.02 + 0.58 ± 0.02 +
Citrate 0.17 ± 0.07 0.20 ± 0.01 0.18 ± 0.09 0.24 ± 0.06 0.11 ± 0.05 0.32 ± 0.10 0.18 ± 0.08 0.16 ± 0.05
Glucose-1-phosphate 4.46 ± 0.65 1.65 ± 0.1 * 4.59 ± 0.40 5.16 ± 0.66 1.69 ± 0.19 2.31 ± 0.13 ◦ 1.71 ± 0.24 1.88 ± 0.14
Amino acids
Alanine 6.02 ± 0.77 7.63 ± 0.33 * 4.88 ± 0.88 5.20 ± 0.79 6.95 ± 0.30 5.40 ± 0.25 6.00 ± 0.48 6.80 ± 0.36
Asparagine 0.18 ± 0.02 0.26 ± 0.03 * 0.19 ± 0.04 0.22 ± 0.03 0.22 ± 0.02 0.18 ± 0.07 0.21 ± 0.03 0.26 ± 0.02
Citrulline 0.19 ± 0.09 0.26 ± 0.09 0.14 ± 0.11 0.18 ± 0.05 0.26 ± 0.07 1.16 ± 0.14 * 0.46 ± 0.18 0.24 ± 0.13
Cysteine 0.56 ± 0.12 0.29 ± 0.07 + 0.40 ± 0.13 0.32 ± 0.04 0.22 ± 0.09 0.38 ± 0.07 0.29 ± 0.15 0.29 ± 0.14
Cystine (Cys-Cys) 0.12 ± 0.04 0.13 ± 0.03 0.12 ± 0.05 0.15 ± 0.04 0.24 ± 0.05 0.47 ± 0.04 + 0.42 ± 0.06 + 0.27 ± 0.04
Glutamate 7.03 ± 0.28 4.94 ± 0.31 * 7.27 ± 0.25 7.12 ± 0.24 5.32 ± 0.15 5.35 ± 0.15 5.14 ± 0.12 5.41 ± 0.20
Glutamine 0.48 ± 0.12 0.72 ± 0.24 0.45 ± 0.14 0.48 ± 0.09 0.94 ± 0.10 0.34 ± 0.09 * 0.66 ± 0.32 0.91 ± 0.11
Glycine 2.18 ± 0.10 2.85 ± 0.03 2.38 ± 0.09 2.21 ± 0.12 2.86 ± 0.06 2.40 ± 0.11 2.65 ± 0.03 2.96 ± 0.07
Histidine 0.19 ± 0.04 0.28 ± 0.02 0.14 ± 0.04 0.16 ± 0.04 0.26 ± 0.02 0.14 ± 0.05 0.21 ± 0.03 0.22 ± 0.04
Isoleucine 0.42 ± 0.18 0.68 ± 0.15 0.35 ± 0.10 0.35 ± 0.10 0.72 ± 0.12 0.68 ± 0.04 0.88 ± 0.11 0.77 ± 0.08
Leucine 4.27 ± 0.18 5.89 ± 0.10 * 3.92 ± 0.16 3.76 ± 0.17 5.95 ± 0.06 4.09 ± 0.18 5.52 ± 0.15 5.19 ± 0.14
Lysine 4.67 ± 0.36 4.26 ± 0.18 5.45 ± 0.24 5.02 ± 0.24 ◦ 4.37 ± 0.27 4.68 ± 0.18 4.08 ± 0.24 4.33 ± 0.25
Methionine 0.95 ± 0.08 1.06 ± 0.07 1.02 ± 0.05 0.98 ± 0.05 1.02 ± 0.05 1.30 ± 0.04 ◦ 1.15 ± 0.05 1.09 ± 0.05
Ornithine 1.84 ± 0.13 1.71 ± 0.03 1.90 ± 0.11 1.72 ± 0.13 1.66 ± 0.02 2.65 ± 0.17 * 1.92 ± 0.12 ◦ 1.81 ± 0.08
Phenylalanine 0.30 ± 0.02 0.33 ± 0.02 0.28 ± 0.02 0.27 ± 0.04 0.29 ± 0.01 0.20 ± 0.04 + 0.25 ± 0.04 0.28 ± 0.02
Pipecolic acid 0.64 ± 0.08 0.69 ± 0.12 0.73 ± 0.08 0.72 ± 0.11 1.00 ± 0.04 1.23 ± 0.06 * 1.07 ± 0.07 1.00 ± 0.10
Proline 0.56 ± 0.12 0.40 ± 0.22 0.50 ± 0.12 0.50 ± 0.12 0.68 ± 0.08 0.54 ± 0.05 0.64 ± 0.17 0.66 ± 0.09
Threonine 2.96 ± 0.12 2.61 ± 0.07 + 3.27 ± 0.12 3.03 ± 0.14 2.75 ± 0.11 2.50 ± 0.07 2.83 ± 0.14 3.00 ± 0.07
Tryptophan 0.11 ± 0.03 0.07 ± 0.03 0.09 ± 0.02 0.10 ± 0.03 0.05 ± 0.02 0.04 ± 0.02 0.08 ± 0.04 0.03 ± 0.01
Tyrosine 0.38 ± 0.04 0.37 ± 0.02 0.37 ± 0.02 0.34 ± 0.02 0.36 ± 0.02 0.26 ± 0.02 * 0.32 ± 0.07 0.36 ± 0.02
Valine 4.24 ± 0.19 5.85 ± 0.08 * 4.72 ± 0.20 4.46 ± 0.26 5.87 ± 0.13 5.27 ± 0.19 5.94 ± 0.25 5.93 ± 0.16
Cofactors
Adenosine triphosphate 0.25 ± 0.03 0.22 ± 0.02 0.27 ± 0.04 0.25 ± 0.03 0.24 ± 0.02 0.26 ± 0.02 0.30 ± 0.05 0.25 ± 0.02
Nicotinamide-adenine-dinucleotide 0.08 ± 0.03 0.06 ± 0.01 0.08 ± 0.01 0.08 ± 0.02 0.07 ± 0.03 0.07 ± 0.02 0.08 ± 0.03 0.08 ± 0.01
Other
Trimethylamine 1.18 ± 0.04 1.09 ± 0.02 + 1.16 ± 0.06 1.16 ± 0.06 1.12 ± 0.03 0.71 ± 0.03 * 0.87 ± 0.08 ◦ 1.04 ± 0.03
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Nine of the metabolites identified, namely, glucose-1-P (Glc-1-P), seven amino acids (alanine,
asparagine, cysteine, glutamine, leucine, threonine, valine), and trimethylamine (TMA) were
significantly different between independent populations of WBC6 wildtype populations (Table 2,
columns on the left). The variability of these nine metabolites may be due to rapid turn-over rates due
to their pivotal roles in energy and intermediary metabolism. Furthermore, the variability may reflect
the potential of the Giardia strain WBC6 to adapt to changing environmental conditions. Consequently,
in order to identify patterns discriminating between strains, these metabolites had to be excluded.
For an overview, principal component analysis (PCA) and orthogonal partial least squares discriminant
analysis (oPLS-DA) plots containing all Giardia strains given in Table 2 are displayed in Figure S1.
2.2. Phenotype and Metabolite Patterns Related to Thioredoxin Reductase Overexpression
Because overexpression of either allele of TrxR had little effect on nitro drug susceptibility, we
investigated whether oxygen differentially affected the growth of strains overexpressing either the
wildtype allele (TrxR) or a dominant negative allele (TrxR DN). There was no marked difference
between the three strains tested under anaerobic growth conditions (Figure 1A). Under semi-aerobic
conditions, however, the untransformed wildtype strain grew only in the presence of more than 10 mM
D-cysteine (D-Cys) added to the medium. The strain overexpressing the dominant negative TrxR allele
started growing already at 2.5 mM D-Cys. The strain overexpressing the wildtype TrxR grew even in
the absence of D-Cys, reaching higher densities after 3 days than the two other strains (Figure 1B).
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direct inactivation of oxygen, not to an indirect effect such as an increased synthesis of Cys-rich 
proteins. The TrxR DN strain may need less D-Cys than the wildtype trophozoites (WT) to resume 
growth because the protein itself may act as a scavenger independently of enzyme activities. 
The comparison of metabolite patterns in G. lamblia trophozoites overexpressing either the 
wildtype thioredoxin reductase (TrxR) or a dominant negative allele (TrxR DN) revealed clear 
clustering of each group in principal component analysis (PCA; Figure 2A). Orthogonal partial least 
squares discriminant analysis (oPLS-DA) showed complete and significant separation between the 
groups along the first, predictive PLS component latent variable (LV) 1 (Figure 2B). 
Figure 1. Thioredoxin reductase protected Giardia lamblia trophozoites from oxygen. Growth of
G. lamblia wildtype trophozoites (WT) and of trophozoites overexpressing either wildtype thioredoxin
reductase (TrxR) or a dominant negative mutant allele (TrxR DN) under anaerobic (A) or semi-aerobic
(B) conditions in medium supplemented with different amounts of D-cysteine (D-Cys).
Our results suggest that TrxR acts as a scavenger of reactive oxygen species, as suggested by
previous studies [5,36]. Because D-Cys is non-proteinogenic, we attribute the protective effect to
a direct inactivation of oxygen, not to an indirect effect such as an increased synthesis of Cys-rich
proteins. The TrxR DN strain may need less D-Cys than the wildtype trophozoites (WT) to resume
growth because the protein itself may act as a scavenger independently of enzyme activities.
The comparison of metabolite patterns in G. lamblia trophozoites overexpressing either the
wildtype thioredoxin reductase (TrxR) or a dominant negative allele (TrxR DN) revealed clear clustering
of each group in principal component analysis (PCA; Figure 2A). Orthogonal partial least squares
discriminant analysis (oPLS-DA) showed complete and significant separation between the groups
along the first, predictive PLS component latent variable (LV) 1 (Figure 2B).
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Figure 2. Principal component analysis (PCA) and orthogonal partial least squares discriminant
analysis (oPLS-DA) of all integral regions (138 buckets) obtained by 1H high-resolution magic angle
spinning (HR-MAS) NMR analysis of TrxR and TrxR DN trophozoites. The ellipses show 83.4%
confidence intervals. The strains are detailed in Table 1. (A) PCA; (B) oPLS-DA. R2 and Q2 values for
the oPLS model are given in Table S2. PC: principal component; LV: latent variable.
A detailed comparison of single metabolites revealed that these differences could be attributed
to acetate, which was significantly increased, and lysine, which was significantly decreased in TrxR
DN as compared to TrxR (Table 2, columns 3 and 4). Other separating contributions only deriv
from metabolites ith pool sizes varying betwee wildtype populations. Because acetate is an i direct
product f PFOR, verexpressors of the wildtype allele may reduce it more efficiently to ethanol
than the overexpressors of the dominant negativ mutant allele. As the catabolism of lysine yields
acetyl-coenzymeA (and thus acetate) as a final product (see [37] and references therein), the increase of
acetate may also be directly linked to an increased cat bolis of lysin , thereby causing the observed
changes in the pool siz s of both met bolit s.
2.3. Metabolite Patterns Related to Nitroreductase Overexpression
When comparing trophozoites overexpressing the nitro reductases NR1, NR2, and NR3 to a
control strain overexpressing glucuronidase A (see Table 1 for phenotypes), PCA resulted in complete
separation of all classes, and oPLS-DA revealed significant differences between all these strains
(Figure 3). More specifically, the NR3 and GusA groups were clustered closer together, whereas the
NR1 group was the furthest away and was already distinguished in PCA from all other groups solely
by its positive scores along principal component (PC) 1 (Figure 3A).
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Figure 3. PCA and oPLS-DA of all integral regions (138 buckets) obtained by 1H-HR-MAS NMR
analysis of GusA, NR1, NR2, and NR3 trophozoites. The ellipses show 83.4% confidence intervals. R2
and Q2 values for the oPLS model are given in Table S2. The strains are detailed in Table 1. (A) PCA;
(B) oPLS-DA.
Upon exclusion of metabolites differing in wildtype population, the most striking differences were
observed in NR1 overexpressing trophozoites, with nine metabolites significantly changed as compared
to the GusA control, namely, acetate, glutamine, phenylalanine, and tyrosine with significantly lower
levels, and cystine, methionine, ornithine, citrulline, and pipecolic acid with significantly higher
levels in NR1 overexpressors as compared to GusA control. Acetate was significantly decreased in
all NR overexpressors as compared to the GusA control (Table 2, columns on the right). In the strain
overexpressing NR2, besides acetate, only ornithine and cysteine followed the same pattern as in the
NR1 overexpressor. In the strain overexpressing NR3, only acetate was significantly affected.
In particular, amino acids generated during the catabolism of the basic amino acids arginine
(ornithine and citrulline) and lysine (pipecolic acid) were significantly increased in NR1 expressing
trophozoites as compared to the GusA control (Table 2).
A typical NMR spectrum representing peaks for ornithine and citrulline from NR1 and GusA
trophozoites is shown in Figure 4.
Thus, taken together, we could identify a distinct pattern of nine metabolites differential between
NR1 and GusA control trophozoites.
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Subsequently, an oPLS-DA model calculated for discrimination between NR1 and GusA (Figure 
5A) was applied to the nitro drug-resistant C4 trophozoites and wildtype trophozoites (WT), as 
shown in Figure 5B. The predictive value of the model led to complete separation of C4 versus WT, 
Figure 4. Representative 1H HR-MAS NMR spectra of suspensions of NR1 and GusA trophozoites in
phosphate buffered saline (PBS). The resonances of citrulline (Ctl) and Ornithine (Orn) between 3.0 and
3.2 ppm are highlighted by the gray box. (A) Spectral region from 1.5 ppm to 4 ppm, (B) highlighted
region in detail.
2.4. Comparison of the NR1 Pattern with the Situation in Nitro Drug-Resistant Trophozoites
These findings prompted us to test whether the pattern obtained by comparing NR1 overexpressing
trophozoites (with an increased susceptibility to NTZ) to GusA control trophozoites could be linked to
the nitro drug susceptibility. For this, we compared the metabolomes of WBC6 wildtype trophozoites
with trophozoites of the nitro drug-resistant strain C4 with reduced NR1 activity. Individual normalized
peak integrals and a comparison of all metabolites between WBC6 and C4 trophozoites are given in
the Suppl me tary Materials section (Tabl S3 and Figure S2).
Subs quently, an PLS-DA model cal ul t for discr minati n between NR1 and GusA (Figure 5A)
was applied to the nitro d ug- esistant C4 trophoz ites and wildtype trophozoites (WT), as shown
in Figur 5B. The pr dict ve value of the model led to compl te separatio of C4 versus WT, that
is, suggesting a correlation betwe n n troreductase ctivity and the metabolome. In a next step, we
plotted he relative chan es observed in NR1 compared o GusA of the nine differential metabolites
listed above v rsus the corresponding relative changes obtained in WT compared to C4 (Figure 5C).
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Figure 5. The metabolic pattern obtained by comparing NR1 versus GusA can be linked to the nitro
drug susceptibility. (A) oPLS-DA score plots displaying the model calculated for distinguishing NR1
from GusA along the latent variable LV 1. (B) Class prediction based on the model shown in (A) applied
to C4 and WT strains. The ellipses show 83.4% confidence intervals. (C) Ratios of the peak integrals of
the eight differential metabolites listed above from NR1/GusA vs. WT/C4. The correlation between
metabolite ratios in G. lamblia NR1 vs. GusA and WT vs. C4 trophozoites (see Table 1) was highly
significant (Pearsons correlation coefficient 0.942; p < 0.0005). R2 and Q2 values for the oPLS model are
given in Table S2.
s s i i re 5 , t e pattern of the nine identified metabolites inversely correlated with a
pattern of the same metabolites in the nitro drug-resistant strain C4, which has lower NR1 levels than
its corresponding wildtype. The correlation was highly significant.
e cata lis f ar i i e, a aj r e er s rce f r . la blia [8,26], is f artic lar i terest
it i t is c text. Citrulline and ornithine, the first a t e sec cata lites f ar i i e, are
siti el c rrelate it 1 le els, ereas l ta i e, a i irect cata lite f r it i e [38], is
egatively correlated with NR1 levels. This suggests that NR1 interferes with the catabolism of arginine.
Because the ATP levels are unaltered in NR1, as well as in all other transgenic trophozoites, a direct
interference with energy supply is unlikely. In G. lamblia, arginine catabolism is not only a major source
for ATP, but has also other functions. Within this context, arginine deiminase (ADI) is of particular
interest. ADI does not only transform free arginine into citrulline [39], b t also arginine residues in a
variety of proteins including variant surface proteins [40]. Accumulation of inhibitory amounts of
citrulline of this enzyme may thus affect regulatory pathways depending on ADI, a “moonlighting”
protein, as evidenced by recent studies [41,42]. Beca se NR1 overexpressed and purified from E. coli
has a much higher quinone than nitroreductase activity in vitro [22,23], it is possible that it interferes
with susceptibility/resistance to nitro compounds, not (only) by direct reduction of these compounds,
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but rather indirectly via reduction of an unknown quinone substrate or by interfering with coenzymes
involved in electron transfer [18]. The exact function of this enzyme remains to be elucidated.
3. Conclusions
In contrast to other organisms, the metabolome plasticity of the early diverging eukaryont
G. lamblia is far from being elucidated, especially in response to genetic transformation and/or
drug-based selection. The present study could therefore be regarded as a paradigm extendable to
studies on other extracellular parasites such as, for example, amebae [2], trichomonads, or even
helminths [43]. These investigations may yield novel antiparasitic drug targets.
4. Materials and Methods
4.1. Biochemicals
If not otherwise stated, all biochemical reagents were from Sigma (St Louis, MO, USA). D2O-based
50 mM phosphate-buffered saline (PBS) was prepared from mixing adequate amounts of 50 mM
K2HPO4 and NaH2PO4 solutions in D2O containing 0.9% NaCl to give a pH of 7.0 (corresponding to a
pD of 7.4).
4.2. Growth of Thioredoxin Reductase Overexpressors
G. lamblia trophozoites overexpressing a wildtype allele of thioredoxin reductase (TrxR), a dominant
negative mutant allele (TrxR DN; see [24]), or wildtype trophozoites were seeded into 96-well plates (103
trophozoites per well) containing normal culture medium or medium supplemented with increasing
amounts of D-cysteine. D-cysteine was used instead of L-cysteine because it is not proteinogenic.
The plates were incubated under anaerobic (85% N2, 10% H2, 5% CO2) or semi-aerobic (85% N2, 10%
CO2, 5% O2) conditions. After 3 days, cells were quantified using the Alamar blue assay, as described
elsewhere [44,45]. The assays were run in quadruplicate.
4.3. Preparation of Cell Samples for HR-MAS NMR
G. lamblia trophozoites from the strains listed in Table 1 were grown to confluence in
modified TYI-S33 medium and harvested by chilling on ice, as previously described [18,23,24].
After centrifugation, trophozoites were washed once in ice-cold PBS, followed by two washes with
ice-cold D2O-based PBS, counted in a Neubauer chamber, and shock frozen in liquid nitrogen.
All samples were stored in aliquots corresponding to 3 × 106 cells at −70 ◦C until further analysis [26].
The nitroreductase overexpressors were compared to a GusA overexpressor and not directly to an
untransfected wildtype strain because all strains had to undergo a selection procedure of transfectants,
which was shown to influence expression of various genes [46].
4.4. HR-MAS NMR Spectroscopy and Processing of Spectra
1H HR-MAS NMR experiments of cell samples were performed on a 500 MHz Bruker Avance II
spectrometer (Bruker BioSpin, Fällanden, Switzerland) with a 4 mm HR-MAS dual inverse 1H/13C
probe equipped with a z-gradient directed along the magic angle axis. Each sample was thawed
during 2 min immediately before HR-MAS NMR measurement. Suspensions corresponding to 3 × 106
cells were filled into ZrO2-HR-MAS rotors with PTFE (Teflon) inserts providing a sample volume
of 50 µL. The sample amount inside the rotor was determined by weight control. The rotor was
spun at a MAS rate of 3 kHz during measurements. The temperature was set to 279 K (nominal),
allowing the sample to equilibrate during 5 min. 1H spectra were recorded using a 1D PROJECT
(periodic refocusing of J evolution by coherence transfer) pulse sequence with water pre-saturation
and a rotor-synchronized T2 filter of 115 ms to suppress broad components with short T2 relaxation
times. Each spectrum was acquired with 1024 scans, a spectral width of 6010 Hz, a data size of 16 k
points, an acquisition time of 1.36 s, and a relaxation delay of 4 s. 1H NMR resonance assignments were
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based on the spectral analysis previously published [26]. To confirm resonance assignments, additional
2D 1H1H-TOCSY spectra were acquired for at least one sample within each sample group using the
DIPSI2 sequence (“dipsi2phpr” from the Bruker pulse program library) with water pre-saturation
during relaxation delay.
Data acquisition and spectral processing were performed with the Bruker TopSpin v 3.2 Pl5
software. All spectra were processed identically—the summed free induction decays (FIDs) were
exponentially multiplied with a line broadening factor of 1 Hz and Fourier transformed. The resulting
spectra were phased and calibrated to the γ-CH3 resonance of threonine (Thr) at 1.326 ppm. Baseline
correction for the spectral region of 0–5.7 ppm was performed by applying a cubic spline function with
individually set baseline points. The spectral region between 5.7 and 10 ppm was baseline-corrected
using the underground removal tool of the Bruker AMIX 3.9.14 software applying a filter of 30 Hz.
4.5. Bioinformatics and Statistical Methods
Statistical analysis of the inhibition tests was performed with suitable tools from the open source
software package R [47]. The results were compared to the controls separately for each strain and
analysed by two-sided paired t-tests. The p-values were corrected for multiple comparisons.
Multivariate statistical data analysis was performed using MATLAB R2012a (Mathworks) and
PLS-Toolbox 7.5.2 (Eigenvector Research, Inc., Manson, WA, USA). The processed NMR spectra were
subdivided into 138 individually sized buckets (integral regions) to cover single resonances as much
as possible in the spectral range between 0 and 10 ppm. Bucket selection was guided by an overlay
of summed spectra from each sample group. The spectral region of the residual water resonance
(4.66–5.2 ppm) and noise regions were excluded. Both bucket selection and integration of bucket
regions were performed with the Bruker TopSpin v 3.2 Pl5 software. The numeric bucket integrals
were exported into the Excel (Microsoft Office Professional Plus 2016) software, and the buckets were
assigned as far as possible to contributing metabolites. The subsequent steps were performed using
the PLS-Toolbox software. Probabilistic quotient normalization (PQN) was applied to the integral
regions to account for different sample amounts [48]. Mean centering was applied to the buckets, as
well as pareto scaling to reduce the relative importance of large values [49]. The samples (spectra)
were grouped according to the corresponding G. lamblia strain, as given in Table 2, and the number
of samples per group was n = 4–10 (Table 2). Principal component analysis (PCA) was applied to
probe for clustering. The first two principal components (PC 1, PC 2) were plotted to generate the PC
score plots to visualize unsupervised variation of the datasets within each group. For testing, if the
groups can be distinguished on the basis of their metabolite spectra, orthogonal partial least squares
discriminant analysis (oPLS-DA) was performed using sample group assignment as y-variables. One to
three latent variables (LV) were calculated, and LV1 and LV2 were plotted to obtain the oPLS-score
plots. When only one LV was calculated (as suggested by the software in order not to overfit the data),
this value was plotted against the Q residuals. For both PCA and oPLS, 83.4% confidence ellipses,
indicating a statistical significant separation of p < 0.05 when not overlapping, were superimposed on
the score plots to illustrate the goodness of class separation [50]. The venetian blinds method was used
for cross validation of the oPLS models. Parameters of the oPLS including the goodness of fit (R2) and
the predictive ability (Q2) are summarized in Table S2.
For univariate statistical analysis, integrals of representative spectral regions for each of the 27
metabolites were evaluated. These integrals were selected such that either single or averages of multiple
isolated resonances from each metabolite were included, minimizing contributions from other metabolite
resonances as much as possible. The selection of integrals is visualized in Figure S3 on representative
spectra. The resonance integrals or corresponding buckets were extracted from the PQN-normalized
data matrix that was created for multivariate statistics, as described above. For each integral, the mean
value and standard deviation was calculated using the Excel software. Single factor ANOVA and t-test
(Excel) were used to probe for metabolite differences between the G. lamblia strains. All p-values were
multiplied with a factor of 27 to correct for multiple comparisons (Bonferroni correction).
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Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/2/53/s1,
Figure S1: PCA and oPLS-DA of all integral regions (138 buckets) obtained by 1H-HR-MAS NMR analysis of
TrxR, TrxR DN, WT1, NR1, NR2, NR3, GusA, and WT2 trophozoites. The strains are detailed in Table 1. A, PCA;
B, oPLS-DA, Figure S2: Metabolites identified in G. lamblia WBC6 wildtype trophozoites (WT, n = 4) and in
trophozoites of the nitro drug-resistant strain C4 (n = 10); mean values ± SD. Metabolites marked with ** and *
were significantly different with p < 0.001 and p < 0.005 respectively according to t-test and correction for multiple
comparisons. Significant levels in gray were excluded from discussion due to high variability between different
WT-batches, Figure S3. Representative 1H HR-MAS NMR spectra of Giardia trophozoites indicating selection of
spectral regions / buckets and their metabolite assignments that were used for integration in univariate analysis.
Ac (acetate) and Ile are better visible in the upper spectrum (A) than in the lower spectrum (A’). For metabolites
marked with * the average of multiple regions as indicated were used. A-D, contiguous spectral regions; Cyn,
cysteine, Table S1: Peak integrals obtained by 1H-HR-MAS NMR analysis of G. lamblia WBC6 wildtype trophozoites
(WT; two independent experiments), in trophozoites overexpressing thioredoxin reductase (TrxR) or a dominant
negative mutation of TrxR (TrxR DN) as a control, and in trophozoites overexpressing the nitroreductases NR1,
NR2, NR3, or GusA as a control, Table S2: Summary of parameters and statistical results of the oPLS-DA shown in
Figures 2, 3 and 5. Table S3: Peak integrals obtained by 1H-HR-MAS NMR analysis of G. lamblia WBC6 wildtype
and nitro drug-resistant C4 trophozoites.
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